Jishan Quan
Jishan Quan has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Yong Jin
College of Pharmacy
7 shared publicationsJingxin Sun
College of Pharmacy
5 shared publications- Guangyu Jin
Jilin Key Laboratory for Immune and Targeting Research on Common Allergic Diseases, Yanbian University, Yanji 133002, China; Department of Radiology, Affiliated Hospital of Yanbian University, No.1327, Juzi Street, Yanji, Jilin Province, 133000, China
4 shared publications Xiaowei Song
Department of Radiology, Affiliated Hospital of Yanbian University , No. 1327, Juzi Street , Yanji 133000 , Jilin Province , P.R. China
3 shared publications- Cheng-Hua Jin
Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, China
2 shared publications Dandan Sun
College of Pharmacy, Yanbian University, Yanji 133000, Jilin Province, P.R. China
2 shared publications
Latest Publications
- 4 March 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (4) , 2526-2542
Nebulized Inhalation of ROS-Responsive Dexamethasone-Loaded Liposomes Enhances Therapeutic Efficacy against Pulmonary Fibrosis
This study aimed to develop and evaluate reactive oxygen species (ROS)-responsive (Thioketal-grafted DSPE-PEG2000, DTP) liposomes loaded with dexamethasone (DTP@DEX-LP) for aerosol inhalation to achieve targeted drug delivery and controlled release in the pulmonary fibrosis microenvironment. DTP@DEX-LP was prepared and optimized. The liposomes were characterized for particle size, zeta potential, encapsulation efficiency (EE), and morphology. Their aerosol performance, ROS-responsive drug release, and cellular uptake were assessed in vitro. In vivo pulmonary deposition, pharmacokinetics, and antifibrotic efficacy were evaluated in a bleomycin-induced mouse model, alongside safety profiling. The optimized DTP@DEX-LP exhibited a uniform particle size of ∼ 115 nm, a high EE of >82%, and desirable aerosol properties (FPF ∼ 50%, MMAD ∼ 4.9 μm). The formulation demonstrated ROS-triggered drug release and enhanced cellular uptake in vitro. Following inhalation, DTP@DEX-LP significantly prolonged lung retention and reduced systemic exposure of DEX compared to controls. In the fibrosis model, DTP@DEX-LP treatment yielded superior therapeutic outcomes, markedly improving survival, and reducing collagen deposition. It also showed a notably improved safety profile, with reduced hepatotoxicity compared to intravenous DEX. The ROS-responsive liposomal system represents a promising inhaled platform for the precise treatment of pulmonary fibrosis, effectively enhancing the therapeutic index of dexamethasone by simultaneously improving its efficacy and mitigating systemic toxicity.
- 4 March 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (4) , 2526-2542
Nebulized Inhalation of ROS-Responsive Dexamethasone-Loaded Liposomes Enhances Therapeutic Efficacy against Pulmonary Fibrosis
This study aimed to develop and evaluate reactive oxygen species (ROS)-responsive (Thioketal-grafted DSPE-PEG2000, DTP) liposomes loaded with dexamethasone (DTP@DEX-LP) for aerosol inhalation to achieve targeted drug delivery and controlled release in the pulmonary fibrosis microenvironment. DTP@DEX-LP was prepared and optimized. The liposomes were characterized for particle size, zeta potential, encapsulation efficiency (EE), and morphology. Their aerosol performance, ROS-responsive drug release, and cellular uptake were assessed in vitro. In vivo pulmonary deposition, pharmacokinetics, and antifibrotic efficacy were evaluated in a bleomycin-induced mouse model, alongside safety profiling. The optimized DTP@DEX-LP exhibited a uniform particle size of ∼ 115 nm, a high EE of >82%, and desirable aerosol properties (FPF ∼ 50%, MMAD ∼ 4.9 μm). The formulation demonstrated ROS-triggered drug release and enhanced cellular uptake in vitro. Following inhalation, DTP@DEX-LP significantly prolonged lung retention and reduced systemic exposure of DEX compared to controls. In the fibrosis model, DTP@DEX-LP treatment yielded superior therapeutic outcomes, markedly improving survival, and reducing collagen deposition. It also showed a notably improved safety profile, with reduced hepatotoxicity compared to intravenous DEX. The ROS-responsive liposomal system represents a promising inhaled platform for the precise treatment of pulmonary fibrosis, effectively enhancing the therapeutic index of dexamethasone by simultaneously improving its efficacy and mitigating systemic toxicity.
- Open Access
- 23 January 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (2) , 197
Development and Systematic Evaluation of a Low-Irritation PFD-AIS Formulation for Pulmonary-Targeted Therapy
Background: To overcome the gastrointestinal and hepatic toxicity of oral pirfenidone (PFD) in the treatment of idiopathic pulmonary fibrosis (IPF), this study systematically constructed a minimal-component, buffer-free pirfenidone aerosol inhalation solution (PFD-AIS), achieving lung-targeted delivery, reduced systemic exposure, and maintained antifibrotic efficacy. Methods: Analytical methods for PFD-AIS, covering content, related substances, aerodynamic particle size distribution (APSD), and delivered dose uniformity, were established. The prescription and preparation process of the formulation was optimized by evaluating its key quality attributes. Pharmacodynamic and pharmacokinetic evaluations of PFD-AIS were performed in a mouse lung-fibrosis model and SD rats. Results: The final specification of PFD-AIS was set to 40 mg:4 mL, containing 40 mg of PFD, 28 mg of sodium chloride, and 4 mL of injection water with a preparation process of 40 °C for 60 min and a pH range of 4–8. The PFD-AIS exhibited a fine particle fraction (FPF) of 56.1%, meeting the requirements for deep lung deposition. The delivered dose and delivery rate were 17.52 mg and 2.48 mg/min, respectively, both complying with inhalation formulation standards. In the bleomycin-induced IPF mouse model, the PFD-AIS markedly improved pulmonary fibrosis pathology, reduced the lung coefficient, and significantly lowered serum ALT/AST levels, indicating hepatic protection. In the SD rats, compared with oral dosing, PFD-AIS administration resulted in significantly lower AUC0−t (−63%) and AUC0–∞ (−67%) values, demonstrating a substantial reduction in systemic drug exposure. Conclusion: This work presents a complete, systematic chain—from formulation, process, and quality control to pharmacodynamics and pharmacokinetics—of a PFD-AIS. The PFD-AIS is effective and feasible, featuring a stable preparation process and controllable quality. Lung-directed drug delivery enhances PFD’s therapeutic efficacy, reduces systemic exposure and liver toxicity, and offers significant clinical advantages.
- 23 January 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (2) , 197
Open AccessDevelopment and Systematic Evaluation of a Low-Irritation PFD-AIS Formulation for Pulmonary-Targeted Therapy
Background: To overcome the gastrointestinal and hepatic toxicity of oral pirfenidone (PFD) in the treatment of idiopathic pulmonary fibrosis (IPF), this study systematically constructed a minimal-component, buffer-free pirfenidone aerosol inhalation solution (PFD-AIS), achieving lung-targeted delivery, reduced systemic exposure, and maintained antifibrotic efficacy. Methods: Analytical methods for PFD-AIS, covering content, related substances, aerodynamic particle size distribution (APSD), and delivered dose uniformity, were established. The prescription and preparation process of the formulation was optimized by evaluating its key quality attributes. Pharmacodynamic and pharmacokinetic evaluations of PFD-AIS were performed in a mouse lung-fibrosis model and SD rats. Results: The final specification of PFD-AIS was set to 40 mg:4 mL, containing 40 mg of PFD, 28 mg of sodium chloride, and 4 mL of injection water with a preparation process of 40 °C for 60 min and a pH range of 4–8. The PFD-AIS exhibited a fine particle fraction (FPF) of 56.1%, meeting the requirements for deep lung deposition. The delivered dose and delivery rate were 17.52 mg and 2.48 mg/min, respectively, both complying with inhalation formulation standards. In the bleomycin-induced IPF mouse model, the PFD-AIS markedly improved pulmonary fibrosis pathology, reduced the lung coefficient, and significantly lowered serum ALT/AST levels, indicating hepatic protection. In the SD rats, compared with oral dosing, PFD-AIS administration resulted in significantly lower AUC0−t (−63%) and AUC0–∞ (−67%) values, demonstrating a substantial reduction in systemic drug exposure. Conclusion: This work presents a complete, systematic chain—from formulation, process, and quality control to pharmacodynamics and pharmacokinetics—of a PFD-AIS. The PFD-AIS is effective and feasible, featuring a stable preparation process and controllable quality. Lung-directed drug delivery enhances PFD’s therapeutic efficacy, reduces systemic exposure and liver toxicity, and offers significant clinical advantages.
- 2 January 2026
- Published by Elsevier in Journal of Industrial and Engineering Chemistry
- Vol. 159, 377-390
Development and quality evaluation of azelastine hydrochloride oral dissolving film
- 2 January 2026
- Published by Elsevier in Journal of Industrial and Engineering Chemistry
- Vol. 159, 377-390
Development and quality evaluation of azelastine hydrochloride oral dissolving film
- 27 December 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 116
The development of ciclesonide dry powder inhalation and preliminary in vivo pharmacokinetic studies in rats
- 27 December 2025
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 116
The development of ciclesonide dry powder inhalation and preliminary in vivo pharmacokinetic studies in rats
- 25 December 2025
- Published by American Chemical Society (ACS) in Journal of Chemical Education
- Vol. 103 (1) , 223-230
Innovation and Practice Research Examining the Teaching Model of a Pharmaceutics Course Under the Background of Industry–Education Integration
- 25 December 2025
- Published by American Chemical Society (ACS) in Journal of Chemical Education
- Vol. 103 (1) , 223-230
Innovation and Practice Research Examining the Teaching Model of a Pharmaceutics Course Under the Background of Industry–Education Integration
- 14 January 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (2) , 787-807
MRI-Based Multifunctional Nanoliposomes for Enhanced HCC Therapy and Diagnosis
The morbidity and mortality rates of hepatocellular carcinoma (HCC) are high and continue to increase. The antitumor effects of single therapies are limited because of tumor heterogeneity and drug resistance, and the lack of real-time monitoring of tumor progression during the treatment process leads to poor therapeutic outcomes. Therefore, novel nanodelivery platforms combining tumor therapy and diagnosis have garnered extensive attention. In this study, we developed a multifunctional nanodelivery vector, LPSD-DOX/siRNA, which was loaded with oleic acid-modified superparamagnetic iron oxide nanoparticles (OA-SPION) and the antitumor drug doxorubicin (DOX), further modified by DOTAP to carry small interfering RNA targeting phosphatidylinositol proteoglycan-3 (Glypican-3, GPC3) (siRNA-GPC3). These components were utilized for the combined treatment of HCC and tumor monitoring with magnetic resonance imaging. LPSD-DOX/siRNA exhibited high drug loading, high gene transfection efficiency, and low toxicity. Pharmacokinetic and in vivo distribution experiments showed that LPSD-DOX/siRNA significantly prolonged the circulation time of DOX and enhanced drug accumulation at the tumor site. Magnetic resonance imaging demonstrated that LPSD-DOX/siRNA can serve as a T2 imaging contrast agent to enhance the imaging contrast between the tumor site and other tissues and facilitate the imaging monitoring of tumor tissues. Antitumor experiments revealed that the effects of DOX were promoted by inhibiting the expression of GPC3 protein in HepG2 cell-transplanted tumors, with increased tumor apoptosis. In conclusion, LPSD-DOX/siRNA serves as a promising strategy for combination therapy and monitoring of HCC, with significant potential in antitumor therapy.
- 14 January 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (2) , 787-807
MRI-Based Multifunctional Nanoliposomes for Enhanced HCC Therapy and Diagnosis
The morbidity and mortality rates of hepatocellular carcinoma (HCC) are high and continue to increase. The antitumor effects of single therapies are limited because of tumor heterogeneity and drug resistance, and the lack of real-time monitoring of tumor progression during the treatment process leads to poor therapeutic outcomes. Therefore, novel nanodelivery platforms combining tumor therapy and diagnosis have garnered extensive attention. In this study, we developed a multifunctional nanodelivery vector, LPSD-DOX/siRNA, which was loaded with oleic acid-modified superparamagnetic iron oxide nanoparticles (OA-SPION) and the antitumor drug doxorubicin (DOX), further modified by DOTAP to carry small interfering RNA targeting phosphatidylinositol proteoglycan-3 (Glypican-3, GPC3) (siRNA-GPC3). These components were utilized for the combined treatment of HCC and tumor monitoring with magnetic resonance imaging. LPSD-DOX/siRNA exhibited high drug loading, high gene transfection efficiency, and low toxicity. Pharmacokinetic and in vivo distribution experiments showed that LPSD-DOX/siRNA significantly prolonged the circulation time of DOX and enhanced drug accumulation at the tumor site. Magnetic resonance imaging demonstrated that LPSD-DOX/siRNA can serve as a T2 imaging contrast agent to enhance the imaging contrast between the tumor site and other tissues and facilitate the imaging monitoring of tumor tissues. Antitumor experiments revealed that the effects of DOX were promoted by inhibiting the expression of GPC3 protein in HepG2 cell-transplanted tumors, with increased tumor apoptosis. In conclusion, LPSD-DOX/siRNA serves as a promising strategy for combination therapy and monitoring of HCC, with significant potential in antitumor therapy.
- 1 May 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 30 (19) , 1507-1518
Construction of GPC3-modified Lipopolymer SiRNA Delivery System
Background: Gene therapy has been widely concerned because of its unique therapeutic mechanism. However, due to the lack of safe and effective carries, it has not been widely used in clinical practice. Glypican 3 (GPC3) is a highly specific proteoglycan for hepatocellular carcinoma and is a potential diagnostic and therapeutic target for hepatocellular carcinoma. Herein, to monitor the effect of gene therapy and enhance the transfection efficiency of gene carriers, GPC3-modified lipid polyethyleneimine-modified superparamagnetic nanoparticle (GLPS), a type of visualized carrier for siRNA (small-interfering RNA) targeting the liver, was prepared. Methods: We performed in vitro gene silencing, cytotoxicity, and agarose gel electrophoresis to identify the optimal GLPS formulation. In vitro MRI and Prussian blue staining verified the liver-targeting function of GLPS. We also analyzed the biocompatibility of GLPS by co-culturing with rabbit red blood cells. Morphological changes were evaluated using HE staining. Results: The GLPS optimal formulation consisted of LPS and siRNA at a mass ratio of 25:1 and LPS and DSPE-PEG-GPC3 at a molar ratio of 2:3. GLPS exhibited evident liver-targeting function. In vitro, we did not observe morphological changes in red blood cells or hemolysis after co-culture. In vivo, routine blood analysis revealed no abnormalities after GLPS injection. Moreover, the tissue morphology of the kidney, spleen, and liver was normal without injury or inflammation. Conclusion: GLPS could potentially serve as an effective carrier for liver-targeted MRI monitoring and siRNA delivery.
- 1 May 2024
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 30 (19) , 1507-1518
Construction of GPC3-modified Lipopolymer SiRNA Delivery System
Background: Gene therapy has been widely concerned because of its unique therapeutic mechanism. However, due to the lack of safe and effective carries, it has not been widely used in clinical practice. Glypican 3 (GPC3) is a highly specific proteoglycan for hepatocellular carcinoma and is a potential diagnostic and therapeutic target for hepatocellular carcinoma. Herein, to monitor the effect of gene therapy and enhance the transfection efficiency of gene carriers, GPC3-modified lipid polyethyleneimine-modified superparamagnetic nanoparticle (GLPS), a type of visualized carrier for siRNA (small-interfering RNA) targeting the liver, was prepared. Methods: We performed in vitro gene silencing, cytotoxicity, and agarose gel electrophoresis to identify the optimal GLPS formulation. In vitro MRI and Prussian blue staining verified the liver-targeting function of GLPS. We also analyzed the biocompatibility of GLPS by co-culturing with rabbit red blood cells. Morphological changes were evaluated using HE staining. Results: The GLPS optimal formulation consisted of LPS and siRNA at a mass ratio of 25:1 and LPS and DSPE-PEG-GPC3 at a molar ratio of 2:3. GLPS exhibited evident liver-targeting function. In vitro, we did not observe morphological changes in red blood cells or hemolysis after co-culture. In vivo, routine blood analysis revealed no abnormalities after GLPS injection. Moreover, the tissue morphology of the kidney, spleen, and liver was normal without injury or inflammation. Conclusion: GLPS could potentially serve as an effective carrier for liver-targeted MRI monitoring and siRNA delivery.
- 13 March 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 269, 116311
Synthesis and anti-liver fibrosis activity of imidazole and thiazole compounds containing amino acids
- 13 March 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 269, 116311
Synthesis and anti-liver fibrosis activity of imidazole and thiazole compounds containing amino acids
- 15 May 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 85
Construction of a visualized liver-targeting siRNA delivery system
- 15 May 2023
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 85
Construction of a visualized liver-targeting siRNA delivery system
- Open Access
- 15 August 2022
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 17 (1) , 952-959
Preparation and evaluation of LA-PEG-SPION, a targeted MRI contrast agent for liver cancer
This study aims to synthesize a magnetic resonance imaging (MRI) contrast agent that can specifically target the asialoglycoprotein receptor of liver cancer cells and evaluate its ability as a targeted MRI contrast agent. Lactobionic acid (LA) and polyethylene glycol (PEG) were used to modify superparamagnetic iron oxide nanoparticles (SPION) to obtain LA-PEG-SPION. LA-PEG-SPION was uniformly spherical under the electron microscope, with regular morphology and good dispersion. The particle size of LA-PEG-SPION was about 30 ± 4.5 nm, and its surface potential was about 31 ± 1.5 mV. LA-PEG-SPION had no toxicity or low toxicity to HepG2 cells and HeLa cells, even at 400 μg/mL. The uptake of LA-PEG-SPION by HepG2 cells was higher than that of SPION, with increased blue-stained particles. The fluorescent labeling rate of HepG2 cells reached 68.8%, which was higher than that of the control group. In vitro, MRI showed that the T2-weighted signal intensity of HepG2 cells was lower than that of the control group. Conclusively, LA-PEG-SPION nanoparticles are synthesized in a simple and efficient way. They are successfully applied to the T2-weighted contrast-enhanced MRI in liver cancer in vitro, and they have the potential to be used for in vivo research and clinical studies.
- 15 August 2022
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 17 (1) , 952-959
Open AccessPreparation and evaluation of LA-PEG-SPION, a targeted MRI contrast agent for liver cancer
This study aims to synthesize a magnetic resonance imaging (MRI) contrast agent that can specifically target the asialoglycoprotein receptor of liver cancer cells and evaluate its ability as a targeted MRI contrast agent. Lactobionic acid (LA) and polyethylene glycol (PEG) were used to modify superparamagnetic iron oxide nanoparticles (SPION) to obtain LA-PEG-SPION. LA-PEG-SPION was uniformly spherical under the electron microscope, with regular morphology and good dispersion. The particle size of LA-PEG-SPION was about 30 ± 4.5 nm, and its surface potential was about 31 ± 1.5 mV. LA-PEG-SPION had no toxicity or low toxicity to HepG2 cells and HeLa cells, even at 400 μg/mL. The uptake of LA-PEG-SPION by HepG2 cells was higher than that of SPION, with increased blue-stained particles. The fluorescent labeling rate of HepG2 cells reached 68.8%, which was higher than that of the control group. In vitro, MRI showed that the T2-weighted signal intensity of HepG2 cells was lower than that of the control group. Conclusively, LA-PEG-SPION nanoparticles are synthesized in a simple and efficient way. They are successfully applied to the T2-weighted contrast-enhanced MRI in liver cancer in vitro, and they have the potential to be used for in vivo research and clinical studies.